Roles of leukemia inhibitory factor receptor in cancer
International Journal of Cancer · 15.01.2025 · 156 (2) · 262-273
DOI: 10.1002/ijc.35157 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 15.09.2024. Verfasst von Wei Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Stomatology, China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Leukemia Inhibitory Factor Receptor alpha Subunit, Neoplasms, Signal Transduction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province, National Natural Science Foundation of China, National Research Project of Chinese Society of Medical Education of Chinese Medical Association.
Abstract (Originalsprache)
Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcription 3. LIF, the most multifunctional cytokines of the interleukin‐6 family acts as both a growth factor and a growth inhibitor in different types of tumors. LIF/LIFR signaling regulates a broad array of tumor‐related processes including proliferation, apoptosis, migration, invasion. However, due to the activation of different signaling pathways, opposite regulatory effects are observed in certain tumor cells. Therefore, the role of LIFR in human cancers varies across different tumor and tissue, despite their recognized value in tumor treatment and prognosis observation is affirmed. Given its aberrant expression in numerous tumor cells and crucial regulatory function in tumorigenesis and progression, LIFR is considered as a promising targeted therapeutic agent. This review provides an overview of LIFR's initiating signaling pathway function as a cytokine receptor and summarize the current literature on the role of LIFR in cancer and its possible use in therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Stomatology, China Medical University, Shenyang, China.
- Department of Clinical Medicine, China Medical University, Shenyang, China.
- Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China.
- Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, China.
- School of Nursing, China Medical University, Shenyang, China.
Förderung
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
- National Research Project of Chinese Society of Medical Education of Chinese Medical Association
Zitieren
APA
Ma, W., Yan, H., Ma, H., Xu, Z., Dai, W., Wu, Y., Zhang, H., & Li, Y. (2025). Roles of leukemia inhibitory factor receptor in cancer. International Journal of Cancer, 156(2), 262-273. https://doi.org/10.1002/ijc.35157
Vancouver
Ma W, Yan H, Ma H, Xu Z, Dai W, Wu Y, et al. Roles of leukemia inhibitory factor receptor in cancer. International Journal of Cancer. 2025;156(2):262-273. doi:10.1002/ijc.35157
BibTeX
@article{Ma2025,
author = {Ma, Wei and Yan, Haixu and Ma, Haoyuan and Xu, Zengyan and Dai, Wei and Wu, Yudan and Zhang, Hongyan and Li, Yanshu},
title = {Roles of leukemia inhibitory factor receptor in cancer},
journal = {International Journal of Cancer},
year = {2025},
volume = {156},
number = {2},
pages = {262--273},
doi = {10.1002/ijc.35157}
}
EUVIMED